We describe how a chance discovery of bacteria that infect stomach linings completely changed how physicians treat ulcers. Specifically, we chronicle how: 1) two Australian physicians brought the bacterial infection to the world's attention and challenged the conventional view that stomach acidity caused ulcers; 2) a global community of researchers helped corroborate the Australians' findings and developed convenient tests and effective treatments; and 3) these tests and treatments were gradually, but not immediately, adopted.
Helicobacter pylori from discovery to acceptance
Australian physicians challenge conventional views (1976-1985)

Early understanding of ulcers
In 1910, Croatian physician, Karl Schwartz, published research suggesting that the excess release of acid could corrode the linings of the stomach and small intestine, causing ulcers. For decades after, researchers and clinicians followed what became known as "Schwartz's dictum": "no acid, no ulcers." Physicians further believed that stress and certain foods increased acid production, inducing ulcers. 5 Even before Schwartz proposed his theory, physicians had prescribed "antacids" --naturally-occurring minerals and metals that neutralize stomach acid -to alleviate ulcer symptoms. These antacids included:
 Calcium carbonate--chewed to relieve stomach pain since ancient times; 6  Magnesium hydroxide--used in Milk of Magnesia since 1872; and  Bismuth--taken in salts since the eighteenth century and in liquid Pepto-Bismol since 1901.
However, antacids provided only temporary relief. When treatments stopped, symptoms returned. In addition, the dietary and lifestyle changes that many physicians suggested to patients to reduce stomach acidity were usually ineffective. 7 
Alternatives to antacids
In 1976, Smith, Kline & French, a one-hundred-and-forty-year-old American pharmaceutical company, introduced a drug to reduce acid production, rather than neutralize the already-produced acid (as antacids did). Many decades of research into the mechanism of acid production enabled development of the drug. In the early 1900s, the Nobel-Prize-winning Russian physiologist Ivan Pavlov had found that signals from the brain prompted acid production, but he had not shown how. Researchers then discovered that the brain's signals triggered the production of hormones, which in turn stimulated acid production by the stomach glands. In the mid-1960s, James W. Black, a Scottish pharmacologist working in Smith, Kline's British laboratory identified the specific hormone responsible: a histamine, dubbed "H2." Black and fellow researchers at Smith, Kline then systematically synthesized and screened compounds that stopped H2 from stimulating acid production. Black had already used this relatively new approach of targeting the action of hormones at ICI Pharmaceuticals, one of the largest companies in Britain; at ICI, Black and his colleagues developed a drug that lowered blood pressure by blocking the hormones that stimulate the heart to pump harder. a Similarly, the "H2 blockers," developed by Black's Smith, Kline team, chemically bonded with the histamine to prevent it from stimulating acid production by stomach glands. 8 Smith, Kline & French sought approval for its most promising H2 blocker from British regulators in 1973. The approval process required developers of new drugs to demonstrate their safety in clinical trials, but, as it happened, the blocker was too toxic to pass. The company's second blocker also failed, but a third was able to demonstrate safety in three years. This H2 blocker was so effective that ulcers healed in about six weeks, although British regulators did not at the time require evidence of effectiveness. After receiving regulatory approval, Smith, Kline started marketing the H2 blocker, named "Tagamet," in the UK in November 1976, and, seven months later, in Canada (where regulators followed the lead of their British counterparts). 9 In October 1976 Smith, Kline & French sought approval to market Tagamet from U.S. Food & Drug Administration (FDA). The FDA approved the application in an exceptionally brief ten months. Normally, American regulators would have required Smith, Kline to demonstrate both the safety and effectiveness of its drug through clinical trials in the United States. However, the FDA made an exception for Tagamet because there were no effective alternative treatments: it accepted Smith, Kline's data from its British trials even though these trials had only shown safety and had been conducted outside the United States. Because the effects of long-term use had not been established, however, the FDA took a cautious approach: it approved Tagamet as an eight-week treatment for ulcers in the small intestine. Then, in 1979, after Smith, Kline & French submitted additional trial results, the FDA broadened its approval to include treatment of stomach ulcers. Tagamet went on to become the best-selling drug in the world at the time, posting global sales of USD$1 billion in 1986. Two years later, Dr. James Black would share in the 1988 Nobel Prize for Physiology and Medicine for his work on the targeted development of H2 blockers and blood-pressure drugs. 10 Even though H2 blockers (which often were prescribed in treatment regimens that included antacids) rapidly healed ulcers, they did not cure the underlying disease. By the mid-1980s, several studies suggested ulcers could recur in as many as a quarter of cases after treatments ended. 11 
A lasting cure
The first step toward a lasting cure for ulcers was taken in 1979 by J. Robin Warren, a pathologist working at the Royal Perth Hospital in Perth, Australia. Although Warren later recalled Perth was a "small, isolated community," 12 physicians at Warren's hospital had begun using newly-available endoscopes to diagnose stomach diseases in the 1970s. Earlier endoscopes --narrow tubes inserted through patients' mouths --had only allowed physicians see the insides of stomachs (to, for instance, observe inflammation). The endoscopes that became available in the 1970s enabled physicians to extract stomach tissue samples through the inserted tubes. When Warren was examining one of these tissue samples (taken from a patient with a stomach disorder) through a microscope he saw an unusual and hitherto-unnamed spiral-shaped bacteria. Over the next two years, he found the same spiral-shaped bacteria in tissue samples taken from thirty-five patients with gastritis and other stomach complaints. 13 In fact, physicians had observed the bacteria, named Helicobacter pylori b in 1989, as early as the midnineteenth century. Some researchers even speculated the bacterium might cause ulcers, but they lacked the tools to isolate and study it. By the time better tools were available, researchers had lost interest as improved personal hygiene (for instance, frequent washing with soap and regular cleaning of teeth) had reduced H. pylori infections in much of the developed world. Throughout the twentieth century, physicians sometimes observed the bacterial infections, but they viewed them as curious byproduct rather than a cause of disease. Others assumed that stomach acid would not allow bacteria to survive and -unlike Warrenignored the possibility of bacterial infections. 14 In 1981, Warren recruited Barry Marshall to help study the stomach-dwelling bacterium he had recently discovered. Marshall, who had just completed his basic medical training, had joined Royal Perth Hospital intending to specialize in cardiology. However, he first had to complete a rotation in gastroenterology and participate in a research project in order to qualify as a cardiologist. Working with Warren would satisfy his research requirement. 15 Initially, Marshall's assignment was routine: to secure more consistently-extracted tissue samples for Warren's analysis and match the analysis with patient symptoms and diagnoses. But Marshall's role then extended far beyond what was necessary to meet his research requirement; he stayed with Warren's project and never went back to cardiology. For two years, he learned to search the U.S. National Library of Medicine's online database, at a time when tools that made searching easy were unavailable. c Through these searches he found previous reports of spiral stomach bacteria, the significance of which had been overlooked. Working with Warren, he studied another hundred stomach tissue samples. Analysis of those samples showed that over half the patients with gastritis had bacterial infections. In addition, Marshall found that bacterial infections were present in over three quarters of patients with stomach ulcers and all of the patients with small intestine ulcers. 
Skeptical reactions
Warren and Marshall reported their findings at conferences in Australia and Europe in 1982. Each also wrote a "letter" (typically, brief reports of preliminary findings) to The Lancet, a prestigious British medical journal, in 1983. 17 Their letters immediately stirred controversy. Physicians could not believe that bacteria could survive in stomach acid, particularly in patients with ulcers thought to be caused by excess acid. In fact, Warren himself had expressed surprise at the bacteria's ability to withstand the stomach's acidity in his Lancet letter. 18 In 1984, Warren and Marshall published an article in The Lancet suggesting that the infections were causing the ulcers in the stomach and small intestine. However, this publication further increased skepticism, because physicians considered stomach ulcers and small intestine ulcers to be separate, unrelated conditions. Moreover, Warren and Marshall could not test their hypothesis by reproducing H. pylori infections in lab animals. 19 In June 1984, Barry Marshall tried -and succeeded -in infecting himself. First, colleagues extracted tissue samples showing Marshall's stomach was infection-free. Marshall then drank a broth containing H. pylori taken from one of his patients. In a week, he experienced fatigue and vomiting. Four days after that, Marshall's colleagues extracted additional samples that showed inflammation and an H. pylori infection. The experiment became famous shortly after it was completed, because Robin Warren told the story of what his collaborator had done to himself to a journalist from U.S. tabloid newspaper, The Star. The tabloid's story --"'Guinea Pig' Doctor Discovers New Cure for Ulcers … and the Cause" -was picked up by other newspapers and magazines, including The New York Times, and was retold in popular accounts of the discovery for years thereafter. Marshall and his colleagues published their experiment in an Australian medical journal in April 1985. (Contrary to popular belief, however, Marshall did not require antibiotics to cure himself; his immune system was able to clear the infection in two weeks.) 20 
Global community develops tests and treatments (1984-1993)
Skepticism persisted
Marshall's dramatic experiment did not immediately change medical beliefs or practice. Many physicians continued to question the causal connection between the bacteria and ulcers, because not everyone who had an H. pylori infection developed stomach inflammation or ulcers. (As with Marshall, some people's immune systems may have kept the disease in check.) And, as a practical matter, diagnosis and treatment was difficult. Lab analyses of the stomach tissue samples could take up to a week to complete due to the time required to grow the bacteria in a lab dish, and standard antibiotic treatments failed to eradicate H. pylori infections in three quarters of patients. 21 However, researchers -some sympathetic, some skeptical -continued to investigate H. pylori. This provided the groundwork for better tests and treatments -and, eventually, acceptance of Warren and Marshall's claims.
Convenient tests developed and introduced
Research supporting the development of diagnostic tests advanced first. In 1984, microbiologists at the University of Amsterdam's Academic Medical Center reported abnormal amounts of the digestive stomach enzyme, "urease," in H. pylori-infected tissue samples. Urease could be easily detected because it changes the color of urea (excreted in urine) from bright yellow to pink, just as acid turns blue litmus paper red. 22 Thus, inferring an H. pylori infection from a urease test was potentially quicker and cheaper than testing for the bacterium itself. 23 Marshall led the effort to develop such a urease test. He worked with an Australian diagnostics company, Delta West, although he had by then joined the University of Virginia's medical school, in the United States. Delta West introduced its first a urease test kit in Australia in 1987. 24 In May 1988, Delta West applied to the FDA for permission to market the test kits in the United States. This application was quickly approved -without a clinical trial -under the so-called "510(k)" exemption. (The FDA grants such exemptions to new devices and tests that it decides are "substantially equivalent" to existing devices and tests). Once approved, the test kits could be used by physicians to rapidly identify H. pylori-infected tissue samples in their offices, clinics, and hospitals, rather than sending the samples to a lab. 25 Blood tests then made diagnoses even more convenient. The tests were based on the discovery, made by German researchers in 1988, of antibodies produced by the immune systems of patients with H. pylori infections. Unlike urease testing, which required extracting stomach tissue, detecting the antibodies only required drawing blood. 26 Quidel, a California diagnostics company, was the first to develop blood tests for the H. pylori antibodies, securing approval from the FDA in 1991, also under the 510(k) exemption. The next year, the FDA approved Quidel's second, so-called "finger-stick" blood test for use in doctors' offices; that test required just a drop of blood, rather than a vial that had to be sent out to a lab. 27 
Effective treatments developed
Advances in treatments followed soon after advances in tests. In 1985, microbiologists who worked in a pathology (rather than research) lab in a major regional hospital in Birmingham, England, reported that H. pylori had developed resistance to some antibiotics; this explained why some of the early eradication attempts had been ineffective. 28 In 1988, Marshall and his University of Virginia colleagues found that the potency of other antibiotics that had been only moderately effective when taken alone increased when taken with an antacid. 29 Over the next few years, researchers at academic medical centers in Sweden, The Netherlands, and Australia developed even more effective treatments that combined antibiotics with acid-reducers. d These combinations healed ulcers in ninety-five percent or more cases-whereas previous treatments had done so in seventy percent or fewer cases. Remarkably, after treatments ended, patients in one study had been tracked for four years--and their ulcers had not returned. 30 Some of these combination treatments included a newly-available class of acid-reducers-"proton pump inhibitors" (PPIs) developed by Astra, a longtime Swedish pharmaceutical company. Astra had started testing potential acid-reducing compounds at its research lab in Gothenburg, Sweden, around the same time that Smith, Kline had started H2 blocker research in England in the 1960s. In 1974, Astra's researchers discovered a compound that reduced stomach acidity, but it turned out to also suppress hormone production in the thyroid and cause cancer in the thymus gland. 31 The Swedish researchers tried to synthesize a less toxic compound, but failed. 32 Researchers from the Deep South American state of Alabama helped Astra's Swedish researchers overcome these problems. In 1960, the inventor of modern endoscopes, a London-trained South African, had founded an exceptionally strong gastroenterology research program at the University of Alabama. Researchers from the program, who had studied the stomach's acid secretion for ten years, discovered that while the H2 histamine stimulated acid production by the stomach gland, an enzyme (colloquially known as a "proton pump") pumped out the acid that the gland had produced. A chance meeting of the Alabama and Astra researchers at a 1977 conference in Sweden led to them to speculate that Astra's compound worked by disrupting the action of the proton pump enzyme. 33 The researchers collaborated to systematically synthesize and tested less toxic compounds that targeted the proton pump enzyme, just as the researchers at Smith, Kline had previously targeted the histamine that d Combinations of antibiotics had also been used to eradicate infections in the 1950s. However, retroactive studies conducted by the FDA in the 1960s found those combinations to be significantly less effective than producers had claimed and use had been discontinued. Thereafter, the FDA held combination treatments to more stringent standards of safety and effectiveness. In the mid1990s, combination treatments of antiviral drugs would famously bring the HIV/AIDS epidemic to a halt. stimulated acid production. e By 1980, their collaboration had produced a safe proton pump inhibitor (or PPI). Clinical trials in two Swedish university hospitals showed that the PPI healed ulcers faster than H2 blockers, and fewer ulcers recurred after treatment ended. On the basis of these results, European regulators approved Astra's PPI in 1988, and American regulators followed in 1990. f By 1993, Swedish and Australian researchers had shown that a PPI combined with antibiotics healed ulcers and eradicated H. pylori infections faster than other combinations, with the lowest rates of ulcer recurrence. 34 Research on drug combinations in the U.S. benefitted from the FDA's loose enforcement of rules for testing new uses for already approved drugs. Although in principle the FDA requires pre-approval of such tests, in practice it often does not penalize researchers who do not seek pre-approval. The drugs tested for H. pylori treatments--antibiotics, antacids, H2 blockers, and PPIs-had already been approved. Therefore, researchers could-and did--run trials combining these drugs without seeking FDA pre-approval. 35 
Widespread research and improved tests and treatments sway some skeptics
Researchers in Australia, Europe, and the United States-including a few who had started out as critics of Marshall and Warren 36 --achieved the advances described above, such as identification of the H. pylori antibody and development of antibiotic combinations capable of eradicating H. pylori infections. They included gastroenterologists and pathologists, like Marshall and Warren, who did clinical research, as well as many microbiologists. Many of these researchers worked in academic centers, such as the prestigious University of Alabama program. However, their research was supplemented by research conducted by practicing physician who did not normally publish research. These physicians treated patients in hospitals and clinics in over fifty countries, including: Brazil, Chile, China, Czechoslovakia, Fiji, Greece, Hungary, India, Japan, Kenya, Kuwait, Malaysia, Mexico, Pakistan, Panama, Poland, Romania, Rwanda, Saudi Arabia, Senegal, South Africa, Spain, Tonga, Tunisia, and Yugoslavia. Although these practicing physicians' studies ran for short periods and had small sample sizes, their findings swayed skeptical physicians' opinions. 37 Results of large, longer-term, systematic, controlled trials, published in 1992 and 1993, then conclusively corroborated the results of these many small studies. The results showed that ulcers did not return for at least two years after patients' H. pylori infections had been eradicated with combination regimens. 38 In 1994, the National Institutes of Health, a U.S. government agency that funds medical research, organized a consensus conference on H. pylori. The American College of Gastroenterology, a professional organization that supports research and education, followed in 1996. That same year, European researchers and public health officials also organized a consensus conference in Maastricht, Netherlands. Experts at all three conferences declared H. pylori the cause of almost all ulcers g and recommended widespread testing and treatment of ulcer patients. 39 In 1994, the same year of the first consensus conference in the U.S., the World Health Organization designated H. pylori a cancer-causing agent. 40 The designation had been prompted by studies that tested e The history of H2 blockers and PPIs demonstrates two contrasting approaches to drug discovery. Both companies started research around the same time in the 1960s. Astra took the traditional approach of synthesizing and testing many compounds until it found one that had the desired effect--the reduction of acid in the stomach. A decade later, Astra had an effective -but toxic -drug, and research had stalled. By contrast, Smith, Kline used the new "rational" approach to drug design. Their researchers identified a target molecule crucial to the production of acid and synthesized and tested compounds that disrupted the functioning of that molecule. A decade later, Smith, Kline launched Tagamet. Astra abandoned their traditional approach after meeting the Alabama researchers; thereafter, they designed and tested drugs that targeted the proton pump in the stomach gland.
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over 5,000 patients across Europe, the United States, Japan, and China. The results revealed that those with H. pylori infections were up to six times more likely to develop stomach cancer. 41 
Gradual adoption (1994-2005)
Publicity helps increase testing
By the mid-1990s, nearly all gastroenterologists and about two-thirds of general physicians in the United States reported testing for H. pylori. Increased testing had been spurred in part by wide media coverage. For instance, reporters at national newspapers (e.g. The New York Times, The Wall Street Journal, and USA Today), regional newspapers (e.g. the St. Petersburg Times), general interest magazines (e.g. The New Yorker, Reader's Digest, and Fortune), and on television (NBC Nightly News) interviewed pioneer Barry Marshall (who was already well-known for his 1984 self-experiment) and other researchers. 42 FDA approval of urease breath tests in 1996 further encouraged testing. Previous urease tests, required trained gastroenterologists to extract stomach tissue. The breath tests, which could be administered by general physicians, simply required patients to swallow tablets. The tablets released traceable particles when they encountered urease in the stomach. Then the patients breathed into balloons that were sealed and sent to a lab that would test for the urease-released particles. 43 Barry Marshall had collaborated with Tri-Med, an American startup, to develop a urease breath test in the late 1980s. A test had also been concurrently developed by physicians at Baylor College of Medicine, in Houston, Texas, for Meretek, an American diagnostics company. However, an FDA ruling that breath tests were not substantially equivalent to tests that had already been approved slowed their introduction, because Tri-Med and Meretek had to conduct clinical trials to demonstrate the safety and effectiveness of their tests. The FDA also required two applications for the tests -one for a new drug (the tablet) and one for a new device (the balloon). In 1996, the FDA approved Meretek's test but rejected Tri-Med's applications on the grounds that they had not shown effectiveness. Tri-Med conducted more trials and submitted the results to the FDA the next year, after which its test, too, received approval. 44 Blood tests for H. pylori antibodies also became more widely available. As mentioned, Quidel had offered the first H. pylori blood test in 1991. In the next seven years, over twenty-five diagnostics companies added blood tests to their offerings. 45 (See Exhibit 3 for a list of producers.)
The wider availability of improved tests helped broaden testing: in 1998, a survey showed that nearly all of American physicians said they routinely tested patients with ulcer symptoms for H. pylori. 46 
Treatments lag tests
Physicians did not immediately follow the treatment guidelines set in 1994 by government agencies and professional organizations. h Studies from the mid-1990s suggested physicians prescribed the recommended combinations of antibiotics and acid-reducers only about three to fifteen percent of the time. Instead, they prescribed H2 blockers or PPIs, which patients usually had to continue to take because H2 blockers and PPIs alone did not eradicate H. pylori infections. Observers speculated that one reason why physicians stayed with H2 blockers and PPIs was that pharmaceutical companies, whose representatives play an important role in disseminating information about new treatments, did not market the eradication combinations specified by the treatment guidelines. And, indeed FDA rules prevented such marketing: physicians could prescribe combinations containing antibiotics that the FDA has already approved for other diseases to ulcer patients. However, pharmaceutical companies could not market the antibiotics and antibiotic-containing combinations recommended by guidelines as treatments for ulcers without obtaining h Unlike in the case of HIV/AIDS, H. pylori infections were not immediately life threatening, so the changes in treatment practices may have seemed less urgent. additional FDA approvals. And, concerns about antibiotic resistance (which many physicians also shared) made the FDA reluctant to approve the marketing of antibiotics i for new uses. 47 Patients who were prescribed the recommended combinations also often had difficulty following them, because they required taking up to sixteen pills per day for ten to fourteen days. With H2 blockers or PPIs treatments, patients had to take just two to four pills per day. 48 In 1996, the FDA allowed pharmaceutical companies to market individual antibiotics as well as three combinations containing antibiotics as treatments for ulcers. The approvals of the combination treatments were considered "highly unusual" by observers because the applications had been supported by studies that had measured different outcomes. For instance, some studies measured ulcer healing rates, others eradication rates, and still others rates of ulcer recurrence. To avoid such inconsistencies in the future, the FDA also standardized the clinical trial requirements for H. pylori combinations that would be used to guide pharmaceutical companies as they ran trials and submitted applications. The FDA approvals encouraged the multinational pharmaceutical companies (who produced the individual drugs) to actively market the drugs and combinations that eradicated H. pylori infections to physicians. 49 (See Exhibit 3 for a list of producers).
After companies started marketing H. pylori eradication treatments, their use rapidly increased. In a 1998 survey, about seventy percent of American gastroenterologists and general practitioners surveyed reported routinely prescribing eradication regimens according to guidelines (up from fewer than fifteen percent in 1995 surveys). 50 In the late 1990s, Glaxo Welcome (UK), makers of an H2 blocker, and Pepto-Bismol (U.S.), makers of bismuth, introduced FDA-approved combinations in convenient pill "packs." The new packs increased patient compliance by reducing the number of pills taken by half (to eight per day, down from sixteen). Within a few years, Astra (Sweden) and TAP (U.S./Japan), both makers of PPIs, also offered combinations in packs. 51 
Testing and Treatment in Europe and Japan
As in United States, publicity in Europe -for instance, the 1994 BBC documentary "Ulcer Wars" -helped promote testing but did not immediately increase the prescription of recommended treatments. 52 In the mid-1990s, European physicians tested ulcer patients for H. pylori over three-quarters of the time. However, they prescribed the recommended eradication treatments only about four percent of the time. A few years later, after better tests and treatments became available in Europe, surveys showed physicians tested almost all ulcer patients. And, doctors in some parts of Europe had switched to prescribing the recommended treatments in over ninety percent of patients who had been found to have H. pylori infections. 53 Adoption of both testing and treatment lagged in Japan. An estimated sixty percent of adults -relatively high for a developed country -had infections. And, about 50,000 people died of stomach cancer each year, leading many Japanese researchers to study H. pylori's links to stomach cancer. However, Japanese officials did not approve insurance payments (under the country's insurance programs j ) for eradication treatments until 2000. In addition, for ten years the Japanese government allowed insurance reimbursement of H. pylori testing and treatment for only patients with ulcers -but not those with stomach cancer. Government officials expanded coverage in 2010, after a large-scale, controlled trial conducted at medical centers throughout Japan had shown eradication of infections reduced stomach cancer rates among those treated. 54 i The FDA may have also been reluctant to issue such approvals due to previous problems with the effectiveness of antibiotic combination treatments in the 1950s and 1960s. j The Japanese government required all residents to buy health insurance (either through an employer or government-run program).
The government also set the fee schedule for all health care providers. 
Epilogue
Reluctance to eradicate H. pylori infections diminished overall after results of studies conducted worldwide the 2000s suggested eradication could prevent over seventy-five percent of stomach cancer cases. Studies conducted in the China, Japan, and the UK also suggested that mass H. pylori screening of adults (including people who had no symptoms) and eradication of any infections found would be clearly cost effective in combatting stomach cancer. Advocates of treating infected patients before they had ulcers organized a conference in 2014 in Kyoto, Japan, to set new global guidelines for screening and treatment. The guidelines adopted at the conference recommended testing patients when they exhibited the first symptoms of gastritis. 55 However, some researchers questioned the wisdom of mass screening and treatment. For instance, Dr. Martin Blaser, who helped establish the link between H. pylori and stomach cancer in the early 1990s, voiced concerns about the unintended consequences of eradication in a New Yorker article in 2012. Blaser and others pointed to research that suggested that H. pylori infections did not always cause ulcers and sometimes promoted good health by reducing the risks of developing obesity, asthma, and throat cancer. Other researchers noted that H. pylori had developed resistance to more antibiotics and poorly controlled use of antibiotics for ulcers had increased resistance among bacteria that caused other diseases. Still other researchers asked whether widespread screening and treatment would be cost effective in all nations, or only in some (for instance, in those countries with high rates of stomach cancer). 56 Researchers are now trying to overcome these concerns. Efforts include conducting more rigorous, large-scale trials to evaluate the benefits and risks of eradication, developing new genetic tests to better tailor treatments, and synthesizing antibiotics that can only affect H. pylori to reduce the risk of making other bacteria resistant to more widely used antibiotic treatments. In addition, researchers have been testing H. pylori treatments made of "nanoparticles" that reduce the amount of antibiotics needed to eradicate the infection. Such treatments could further help to reduce the risk that other bacteria develop resistance to antibiotics. 57 Tests, 1980s-1990s Note:
Exhibits Exhibit 1 Overview of H. pylori
Later blood tests to detect H. pylori antibodies achieved accuracy rates of 98% sensitivity and 94% specificity.
Sources: Medical World News (1987) and Sources: , and the FDA PMA and 510(k) online databases.
